Drugs / VYNT-0126
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05625568 | Mar 2023 → Mar 2024 | Rett syndrome | Vyant Bio | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VYNT-0126 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05625568 ↗ |
| Route | Oral | “Liquid for oral administration once daily” NCT05625568 ↗ |